Noa Therapeutics
Cambridge, United States· Est.
A biotech startup using biased AhR modulation to create disease‑modifying small‑molecule therapies for chronic inflammation.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
A biotech startup using biased AhR modulation to create disease‑modifying small‑molecule therapies for chronic inflammation.
ImmunologyGastroenterologyDermatology
Technology Platform
Biased, non‑canonical AhR modulation using precision small‑molecule ligands that selectively activate therapeutic transcriptional pathways while sparing deleterious ones.
Opportunities
First‑in‑class biased AhR modulators could capture unmet need in IBD and dermatology, offering oral, disease‑modifying therapies with superior safety.
Risk Factors
Scientific uncertainty around AhR bias, potential off‑target toxicities, and lack of regulatory precedent for this modality.
Competitive Landscape
Competes with biologics and JAK inhibitors in I&I; differentiation lies in oral delivery, dual immune‑barrier mechanism, and novel AhR target.